293 related articles for article (PubMed ID: 21852468)
1. Infectious diseases. Drug developers finally take aim at a neglected disease.
Leslie M
Science; 2011 Aug; 333(6045):933-5. PubMed ID: 21852468
[No Abstract] [Full Text] [Related]
2. Chagas Disease: A Solvable Problem, Ignored.
Tarleton RL
Trends Mol Med; 2016 Oct; 22(10):835-838. PubMed ID: 27523778
[TBL] [Abstract][Full Text] [Related]
3. Specific chemotherapy of Chagas disease: controversies and advances.
Urbina JA; Docampo R
Trends Parasitol; 2003 Nov; 19(11):495-501. PubMed ID: 14580960
[No Abstract] [Full Text] [Related]
4. Lead identification to clinical candidate selection: drugs for Chagas disease.
Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
[TBL] [Abstract][Full Text] [Related]
5. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.
Zingales B; Miles MA; Moraes CB; Luquetti A; Guhl F; Schijman AG; Ribeiro I; ;
Mem Inst Oswaldo Cruz; 2014 Sep; 109(6):828-33. PubMed ID: 25317712
[TBL] [Abstract][Full Text] [Related]
6. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase.
Mc Carthy OK; Schipani A; Buendía AM; Ruiz-Perez LM; Kaiser M; Brun R; Pacanowska DG; Gilbert IH
Bioorg Med Chem Lett; 2006 Jul; 16(14):3809-12. PubMed ID: 16677813
[TBL] [Abstract][Full Text] [Related]
8. [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].
Andrade SG; Figueira RM
Rev Inst Med Trop Sao Paulo; 1977; 19(5):335-41. PubMed ID: 416483
[No Abstract] [Full Text] [Related]
9. Advances in Chagas disease drug development: 2009-2010.
Buckner FS; Navabi N
Curr Opin Infect Dis; 2010 Dec; 23(6):609-16. PubMed ID: 20885320
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease.
Martín-Escolano R; Aguilera-Venegas B; Marín C; Martín-Montes Á; Martín-Escolano J; Medina-Carmona E; Arán VJ; Sánchez-Moreno M
ChemMedChem; 2018 Oct; 13(19):2104-2118. PubMed ID: 30098232
[TBL] [Abstract][Full Text] [Related]
11. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
12. Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice.
Rivarola HW; Fernández AR; Enders JE; Fretes R; Gea S; Suligoy M; Palma JA; Paglini-Oliva P
Ann Trop Med Parasitol; 1999 Oct; 93(7):695-702. PubMed ID: 10715697
[TBL] [Abstract][Full Text] [Related]
13. Novel drug discovery for Chagas disease.
Moraes CB; Franco CH
Expert Opin Drug Discov; 2016; 11(5):447-55. PubMed ID: 26967915
[TBL] [Abstract][Full Text] [Related]
14. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
15. Applicability of plant-based products in the treatment of Trypanosoma cruzi and Trypanosoma brucei infections: a systematic review of preclinical in vivo evidence.
Pereira RM; Greco GMZ; Moreira AM; Chagas PF; Caldas IS; Gonçalves RV; Novaes RD
Parasitology; 2017 Sep; 144(10):1275-1287. PubMed ID: 28578742
[TBL] [Abstract][Full Text] [Related]
16. The translational challenge in Chagas disease drug development.
Kratz JM; Gonçalves KR; Romera LM; Moraes CB; Bittencourt-Cunha P; Schenkman S; Chatelain E; Sosa-Estani S
Mem Inst Oswaldo Cruz; 2022; 117():e200501. PubMed ID: 35613156
[TBL] [Abstract][Full Text] [Related]
17. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
[TBL] [Abstract][Full Text] [Related]
18. Chagas Disease Treatment: From New Therapeutic Targets to Drug Discovery and Repositioning.
Miranda MR; Sayé MM
Curr Med Chem; 2019; 26(36):6517-6518. PubMed ID: 31849285
[No Abstract] [Full Text] [Related]
19. Recognition for Chagas disease.
Burki T
Lancet Infect Dis; 2019 Jul; 19(7):699. PubMed ID: 31250822
[No Abstract] [Full Text] [Related]
20. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
